Targeted polymeric nanoparticles for cancer gene therapy

Imagem de Miniatura
Arquivos
art_KIM_Targeted_polymeric_nanoparticles_for_cancer_gene_therapy_2015.PDF (2.31 MB)
Citações na Scopus
38
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
KIM, Jayoung
WILSON, David R.
GREEN, Jordan J.
Citação
JOURNAL OF DRUG TARGETING, v.23, n.7-8, p.627-641, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In this article, advances in designing polymeric nanoparticles for targeted cancer gene therapy are reviewed. Characterization and evaluation of biomaterials, targeting ligands, and transcriptional elements are each discussed. Advances in biomaterials have driven improvements to nanoparticle stability and tissue targeting, conjugation of ligands to the surface of polymeric nanoparticles enable binding to specific cancer cells, and the design of transcriptional elements has enabled selective DNA expression specific to the cancer cells. Together, these features have improved the performance of polymeric nanoparticles as targeted non-viral gene delivery vectors to treat cancer. As polymeric nanoparticles can be designed to be biodegradable, non-toxic, and to have reduced immunogenicity and tumorigenicity compared to viral platforms, they have significant potential for clinical use. Results of polymeric gene therapy in clinical trials and future directions for the engineering of nanoparticle systems for targeted cancer gene therapy are also presented.
Palavras-chave
Cancer therapy, cell-specificity, gene delivery, nanoparticles, polymeric biomaterial, promoter, targeting ligands, tissue-specificity
URI
https://observatorio.fm.usp.br/handle/OPI/14420
Referências
  1. Alberts B., 2002, MOL BIOL CELL
  2. DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149
  3. Chen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136
  4. Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125
  5. Poon Z, 2011, NANO LETT, V11, P2096, DOI 10.1021/nl200636r
  6. Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
  7. Francis SM, 2014, MOL THER, V22, P1643, DOI 10.1038/mt.2014.24
  8. Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
  9. Jeong GJ, 2007, J CONTROL RELEASE, V118, P118, DOI 10.1016/j.jconrel.2006.12.009
  10. Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145
  11. Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947
  12. YOKOTA J, 1988, ONCOGENE, V2, P283
  13. Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81
  14. Peng SF, 2009, BIOMATERIALS, V30, P1797, DOI 10.1016/j.biomaterials.2008.12.019
  15. Barh D, 2010, CURR ONCOL, V17, P70
  16. KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107
  17. Cohen JL, 2011, BIOCONJUGATE CHEM, V22, P1056, DOI 10.1021/bc100542r
  18. BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7
  19. [Anonymous], 2000, PROG INFLAM RES
  20. Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
  21. Minn I, 2014, ADV CANCER RES, V124, P131, DOI 10.1016/B978-0-12-411638-2.00004-5
  22. Xiong J, 2012, CANCER-AM CANCER SOC, V118, P536, DOI 10.1002/cncr.26289
  23. Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
  24. Fields RJ, 2012, J CONTROL RELEASE, V164, P41, DOI 10.1016/j.jconrel.2012.09.020
  25. Zhang LX, 2012, CANCER RES, V72, P4276, DOI 10.1158/0008-5472.CAN-12-1013
  26. Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
  27. Moffatt S, 2006, GENE THER, V13, P761, DOI 10.1038/sj.gt.3302721
  28. Kevil C, 1995, ONCOGENE, V11, P2339
  29. Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096
  30. Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
  31. Bishop CJ, 2013, J AM CHEM SOC, V135, P6951, DOI 10.1021/ja4002376
  32. VILE RG, 1993, CANCER RES, V53, P962
  33. Lunsford L, 2000, J DRUG TARGET, V8, P39, DOI 10.3109/10611860009009208
  34. Prabha S, 2004, MOL PHARMACEUT, V1, P211, DOI 10.1021/mp049970+
  35. Tzeng SY, 2013, J BIOMED MATER RES A, V101, P1837, DOI 10.1002/jbm.a.34616
  36. Patel PC, 2010, BIOCONJUGATE CHEM, V21, P2250, DOI 10.1021/bc1002423
  37. Tinsley-Bown AM, 2000, J CONTROL RELEASE, V66, P229, DOI 10.1016/S0168-3659(99)00275-8
  38. Li Q, 2014, CLIN CANCER RES, V20, P2375, DOI 10.1158/1078-0432.CCR-13-1415
  39. Viola JR, 2010, EXPERT OPIN DRUG DEL, V7, P721, DOI 10.1517/17425241003716810
  40. Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
  41. WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
  42. DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315
  43. Anton M, 2005, CANCER GENE THER, V12, P640, DOI 10.1038/sj.cgt.7700829
  44. O'Keefe DS, 2000, PROSTATE, V45, P149
  45. DeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468
  46. Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250
  47. Meric F, 2002, MOL CANCER THER, V1, P971
  48. Struhl K, 1995, ANNU REV GENET, V29, P651
  49. Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856
  50. Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103
  51. Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488
  52. Zhang C, 2010, BIOMATERIALS, V31, P6075, DOI 10.1016/j.biomaterials.2010.04.042
  53. Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
  54. Bhise NS, 2010, BIOMATERIALS, V31, P8088, DOI 10.1016/j.biomaterials.2010.07.023
  55. Menard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425
  56. Huang YH, 2009, CANCER RES, V69, P6184, DOI 10.1158/0008-5472.CAN-09-0061
  57. Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894
  58. Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326
  59. Zhou JB, 2012, NAT MATER, V11, P82, DOI [10.1038/nmat3187, 10.1038/NMAT3187]
  60. Ito T, 2010, BIOMATERIALS, V31, P2912, DOI 10.1016/j.biomaterials.2009.12.032
  61. Guerrero-Cazares H, 2014, ACS NANO, V8, P5141, DOI 10.1021/nn501197v
  62. Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.3.CO;2-I
  63. Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
  64. Goverdhana S, 2005, MOL THER, V12, P189, DOI 10.1016/j.ymthe.2005.03.022
  65. Gao P, 2008, CANCER SCI, V99, P2209, DOI 10.1111/j.1349-7006.2008.00941.x
  66. Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
  67. Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
  68. Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100
  69. Song J, 2004, CANCER RES, V64, P7661, DOI 10.1158/0008-5472.CAN-04-1751
  70. Green JJ, 2007, NANO LETT, V7, P874, DOI 10.1021/nl062395b
  71. Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
  72. Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
  73. Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
  74. WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255
  75. Pan CX, 1999, MED HYPOTHESES, V53, P130, DOI 10.1054/mehy.1998.0731
  76. Rojanarata T, 2008, PHARM RES-DORD, V25, P2807, DOI 10.1007/s11095-008-9648-6
  77. Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2
  78. Hanna N, 2012, CANCER GENE THER, V19, P374, DOI 10.1038/cgt.2012.10
  79. Needham CJ, 2012, BIOMACROMOLECULES, V13, P1429, DOI 10.1021/bm300145q
  80. Maston GA, 2006, ANNU REV GENOM HUM G, V7, P29, DOI 10.1146/annurev.genom.7.080505.115623
  81. Wang DQ, 1999, J CONTROL RELEASE, V57, P9, DOI 10.1016/S0168-3659(98)00099-6
  82. MOCHIZUKI H, 1992, MOL CARCINOGEN, V6, P83, DOI 10.1002/mc.2940060203
  83. Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846
  84. Mastorakos P, 2015, NANOSCALE, V7, P3845, DOI 10.1039/c4nr04284k
  85. Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102
  86. Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
  87. ROSS JF, 1994, CANCER, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
  88. Harris TJ, 2010, BIOMATERIALS, V31, P998, DOI 10.1016/j.biomaterials.2009.10.012
  89. Chen J, 2009, BIOMACROMOLECULES, V10, P2921, DOI 10.1021/bm900724c
  90. Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6
  91. Papadakis ED, 2004, CURR GENE THER, V4, P89, DOI 10.2174/1566523044578077
  92. Bazzoni F, 2001, CANCER RES, V61, P1050
  93. Khan JA, 2007, CHEMBIOCHEM, V8, P1237, DOI 10.1002/cbic.200700165
  94. Bellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
  95. Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
  96. Sakae M, 2008, BIOMED PHARMACOTHER, V62, P448, DOI 10.1016/j.biopha.2007.12.009
  97. Hildebrandt IJ, 2003, GENE THER, V10, P758, DOI 10.1038/sj.gt.3301939
  98. Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
  99. Dutta D, 2007, TOXICOL SCI, V100, P303, DOI 10.1093/toxsci/kfm217
  100. Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]
  101. Li JJ, 2013, CHEM COMMUN, V49, P6974, DOI 10.1039/c3cc43576h
  102. Hayes GM, 2002, CANCER GENE THER, V9, P133, DOI 10.1038/sj.cgt.7700427
  103. Harrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4
  104. Bateman BT, 2001, INFECT IMMUN, V69, P7851, DOI 10.1128/IAI.69.12.7851-7857.2001
  105. Crew JP, 2000, BRIT J CANCER, V82, P161
  106. Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77
  107. WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410
  108. Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
  109. Robson T, 2003, J BIOMED BIOTECHNOL, P110
  110. Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177
  111. Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275
  112. Cohen JA, 2010, ADV MATER, V22, P3593, DOI 10.1002/adma.201000307
  113. Bayele HK, 2005, J PHARM SCI-US, V94, P446, DOI 10.1002/jps.20230
  114. Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107
  115. Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229
  116. Das B, 2004, P NATL ACAD SCI USA, V101, P4839, DOI 10.1073/pnas.0401011101
  117. Boylan NJ, 2012, J CONTROL RELEASE, V157, P72, DOI 10.1016/j.jconrel.2011.08.031
  118. Studeny M, 2002, CANCER RES, V62, P3603
  119. Hsu YY, 1999, J DRUG TARGET, V7, P313
  120. Knapinska AM, 2005, CURR GENOMICS, V6, P471, DOI 10.2174/138920205774482954
  121. Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8
  122. Wang R, 2009, LUNG CANCER, V66, P237, DOI 10.1016/j.lungcan.2009.02.001
  123. GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L
  124. Yadav S, 2009, CANCER CHEMOTH PHARM, V63, P711, DOI 10.1007/s00280-008-0790-y
  125. Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035
  126. Benoit MA, 2001, J DRUG TARGET, V9, P253
  127. Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8
  128. Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
  129. Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
  130. Han SE, 2009, J DRUG TARGET, V17, P123, DOI 10.1080/10611860802472461
  131. Akar U, 2008, AUTOPHAGY, V4, P669
  132. Meyer M, 2009, MOL PHARMACEUT, V6, P752, DOI 10.1021/mp9000124
  133. Gu JJ, 2012, BIOMATERIALS, V33, P644, DOI 10.1016/j.biomaterials.2011.09.076
  134. PANG S, 1995, HUM GENE THER, V6, P1417, DOI 10.1089/hum.1995.6.11-1417
  135. Kurosaki T, 2009, BIOMATERIALS, V30, P2846, DOI 10.1016/j.biomaterials.2009.01.055
  136. Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55
  137. Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G
  138. Buscail L, 2015, MOL THER, V23, P779, DOI 10.1038/mt.2015.1
  139. Walczak H, 1999, NAT MED, V5, P157
  140. Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
  141. Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
  142. Choi KY, 2012, BIOMATERIALS, V33, P6186, DOI 10.1016/j.biomaterials.2012.05.029
  143. Chiu SH, 2004, J CONTROL RELEASE, V97, P357, DOI 10.1016/j.jconrel.2004.03.019
  144. Shmueli RB, 2012, NANOMED-NANOTECHNOL, V8, P1200, DOI 10.1016/j.nano.2012.01.006
  145. Davis ME, 2004, CURR MED CHEM, V11, P179, DOI 10.2174/0929867043456179
  146. Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698
  147. Manome Y, 1998, HUM GENE THER, V9, P1409, DOI 10.1089/hum.1998.9.10-1409
  148. Akinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85
  149. BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
  150. Hu BG, 2014, EXP CELL RES, V324, P183, DOI 10.1016/j.yexcr.2014.04.005
  151. Jafari M, 2012, CURR MED CHEM, V19, P197
  152. Adryan B, 2007, FLY, V1, P142
  153. Sestakova B, 2006, FOLIA BIOL-PRAGUE, V52, P161
  154. Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
  155. Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
  156. Wang Z, 2011, PHARM RES-DORDR, V28, P2983, DOI 10.1007/s11095-011-0604-5
  157. Alvarez RD, 2014, GYNECOL ONCOL, V133, P433, DOI 10.1016/j.ygyno.2014.03.571
  158. Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
  159. Ogris M, 2003, J CONTROL RELEASE, V91, P173, DOI 10.1016/S0168-3659(03)00230-X
  160. Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
  161. Kawashita Y, 1999, HUM GENE THER, V10, P1509, DOI 10.1089/10430349950017842
  162. Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
  163. van Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
  164. Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
  165. Bivas-Benita M, 2004, EUR J PHARM BIOPHARM, V58, P1, DOI 10.1016/j.ejpb.2004.03.008
  166. Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
  167. KOROMILAS AE, 1992, EMBO J, V11, P4153
  168. Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334
  169. Jaggar RT, 1997, HUM GENE THER, V8, P2239, DOI 10.1089/hum.1997.8.18-2239
  170. Labhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+
  171. Smith-Arica JR, 2000, MOL THER, V2, P579, DOI 10.1006/mthe.2000.0215
  172. HARRIS JD, 1994, GENE THER, V1, P170
  173. Klutz K, 2011, MOL THER, V19, P676, DOI 10.1038/mt.2010.296
  174. Bhatia Shilpa, 2013, Discov Med, V15, P309
  175. Bhatnagar A, 2014, CANCER RES, V74, P5772, DOI 10.1158/0008-5472.CAN-14-0018
  176. Buchholz DR, 2012, XENOPUS PROTOCOL POS, P265
  177. Carlberg C, 2014, TRANSCRIPTION FACTOR, P55
  178. Chen JQ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-15
  179. Hyo-eun CB, 2011, NAT MED, V17, P123
  180. Kim J, 2014, BIOCONJUGATE CHEM, V25, P43, DOI 10.1021/bc4002322
  181. Pecot CV, 2014, MOL CANCER THER, V13, P2876, DOI 10.1158/1535-7163.MCT-14-0074
  182. SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
  183. Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
  184. Voellmy R, 2011, J GENET SYNDR GENE T, V2, P107
  185. Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
  186. Yao YD, 2012, SCI TRANSL MED, V4, P130, DOI 10.1126/SCITRANSLMED.3003601
  187. Zarogoulidis P, 2013, J GENET SYNDR GENE T, V4, P1
  188. Zhao XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056395

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - ODS/03